|

Arthritis Clinical Trials in Ohio

31 recruiting studies across 2 cities

Browse by City

Cleveland
24 trials
Columbus
12 trials

All Trials in Ohio

Phase
Trial Phase Dist.
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry—<1 mi
Preventing Injured Knees From osteoArthritis: Severity OutcomesPhase 2<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
The Myelin Disorders Biorepository Project—<1 mi
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisPhase 3<1 mi
IMPACT - AndHealth Autoimmune Research Registry—<1 mi
MOTION Clinical TrialN/A<1 mi
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPhase 2<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPhase 3<1 mi
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry—<1 mi
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension—<1 mi
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisPhase 3<1 mi
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)—<1 mi
Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs PhenotypesN/A<1 mi
Persona Revision Knee System Outcomes—<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPhase 3<1 mi
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabPhase 3<1 mi
RA-PRO PRAGMATIC TRIALPhase 3<1 mi
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Phase 1<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPhase 311 mi
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic ArthritisPhase 311 mi
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPhase 211 mi
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisPhase 211 mi
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Phase 411 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 311 mi
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPhase 211 mi
Safety and Effectiveness of the HIT Reverse HRSN/A13 mi
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip ArthroplastyN/A13 mi
Exactech Shoulder Post Market Clinical Follow-up Study—30 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.